! I’m your host today, Jessica Hergert.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Jeffrey S. Weber, MD, PhD, deputy director and codirector of the Melanoma Research Program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care

 in Melanoma, to discuss some of the main highlights from the 2021 ASCO Annual Meeting in melanoma, including key findings from the phase 3 RELATIVITY-047 trial (NCT03470922), the phase 3 CheckMate-067 trial (NCT01844505), and the phase 3 EORTC 1325/KEYNOTE-054 trial (NCT02362594), among others.

In our exclusive interview, Weber discussed exciting research in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.

Podcasts

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Immunotherapy in Melanoma

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Conference Perspectives

NYU Langone's Perlmutter Cancer Center

Cancer Centers

Partner

Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more. 

Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting